Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.75 EUR
30.35 M EUR
199.72 M EUR
18.53 M
About SHIN NIPPON BIOMEDICAL LABORATORIES
Sector
CEO
Ryoichi Nagata
Website
Headquarters
Tokyo
Founded
1957
ISIN
JP3379950003
FIGI
BBG000BSTF82
Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. Its operations are carried out through the following segments: CRO Business, Translational Research Business, Medipolis Business, and Others. he CRO business is a business that verifies the efficacy and safety of test substances created by clients such as pharmaceutical companies using laboratory animals, cells, and bacteria. The Translational Research Business segment utilizes drug and device development capabilities to accelerate drug development which leads to out-licensing to pharmaceutical companies. The Medipolis Business segment deals with the property management and geothermal power generation businesses. The Others segment engages in the information collection in Europe, which includes real estate and environmental equipment operations. The company was founded in April 1957 and is headquartered in Tokyo, Japan.
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange SHIN NIPPON BIOMED.LAB. stocks are traded under the ticker YB3.
We've gathered analysts' opinions on SHIN NIPPON BIOMED.LAB. future price: according to them, YB3 price has a max estimate of 22.41 EUR and a min estimate of 12.95 EUR. Watch YB3 chart and read a more detailed SHIN NIPPON BIOMED.LAB. stock forecast: see what analysts think of SHIN NIPPON BIOMED.LAB. and suggest that you do with its stocks.
Yes, you can track SHIN NIPPON BIOMED.LAB. financials in yearly and quarterly reports right on TradingView.
SHIN NIPPON BIOMED.LAB. is going to release the next earnings report on Aug 7, 2025. Keep track of upcoming events with our Earnings Calendar.
SHIN NIPPON BIOMED.LAB. revenue for the last quarter amounts to 62.71 M EUR, despite the estimated figure of 61.17 M EUR. In the next quarter, revenue is expected to reach 40.89 M EUR.
YB3 net income for the last quarter is 10.59 M EUR, while the quarter before that showed 11.52 M EUR of net income which accounts for −8.01% change. Track more SHIN NIPPON BIOMED.LAB. financial stats to get the full picture.
SHIN NIPPON BIOMED.LAB. dividend yield was 3.49% in 2024, and payout ratio reached 42.27%. The year before the numbers were 3.29% and 37.63% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. SHIN NIPPON BIOMED.LAB. EBITDA is 32.08 M EUR, and current EBITDA margin is 17.27%. See more stats in SHIN NIPPON BIOMED.LAB. financial statements.
Like other stocks, YB3 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade SHIN NIPPON BIOMED.LAB. stock right from TradingView charts — choose your broker and connect to your account.